The BioCalendar

BioTrinity 2022
2022-04-26 - 2022-04-27
BioTrinity 2022: Catalysing Growth in the Life Sciences Industry
BioTrinity is a proven, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry.
The event is attended by an ever-evolving audience of early stage and emerging life sciences R&D Companies, investors, large pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.
Interacting with new companies each year is something we believe to be a critical attribute of a successful conference and we work hard to ensure that a substantial and fresh line-up of investable opportunities and collaboration possibilities are showcased.

Charles River's 6th Annual Viral Safety and Viral Clearance Summit
2022-04-26 - 2022-04-27
Join us for a two-day event uniting experts on viral safety and viral clearance taking place at the Hyatt Centric Fisherman’s Wharf in San Francisco, CA. Gain insight from expert regulatory authorities, academic researchers, and industry leaders who are defining the way we evaluate biologics, vaccines, and advanced therapeutic medicinal products (ATMPs). Discover new technologies, learn best practices, and achieve a solid understanding for designing an efficient manufacturing process.

WuXi Healthcare Forum 2022
2022-04-26 - 2022-04-28
Dear Colleagues and Friends,
Join thousands from around the world virtually this April 26-28 for the complimentary global WuXi Healthcare Forum 2022 as our industry and R&D ecosystem converge to respond to the World Health Organization’s calls for urgent action to address Noncommunicable Diseases (NCD) – with cardiovascular diseases, cancer, and neurological disorders as the top challenges – which are collectively responsible for almost 70% of all deaths worldwide.
A vital opportunity to take actions on topics that matter –
• Rising to the Challenge: Why are the challenges facing our ecosystem so urgent? What’s holding us back from making new progress? How do we continue to break through barriers? AstraZeneca’s BioPharmaceuticals R&D Chief Sir Menelas Pangalos, Director of NINDS/NIH, Walter Koroshetz, Chief Science & Medical Officer of American Heart Association, Mariell Jessup, CVCT Forum Chair, Faiez Zannad, Chief Patient Officer of American Cancer Society, Arif Kamal, CEO-Partner of Flagship Pioneering, Stephen Hahn, and J&J’s External Innovation Chief, William Hait, will share their perspectives and vision for the future.
• Moving the Needle in Neurological Disorders: A dynamic VC roundtable featuring Laurence Barker of The Dementia Discovery Fund, Philip Scheltens of the Dementia Fund at EQT Life Sciences, Christina Isacson of Lightstone Ventures, and Rana Al-Hallaq of Pfizer Ventures.
• Spotlight on Parkinson’s Disease: To highlight Parkinson’s Disease Awareness Month this April, we will showcase the unique challenges and opportunities facing the development of new therapeutics for PD’s with a dialogue between Todd Sherer of the Michael J. Fox Foundation and Andrew Siderowf of the University of Pennsylvania School of Medicine.
• Revitalizing Cardiovascular R&D: What are the rate-limiting steps of CVD R&D? How can we move the dial on drug discovery & development towards finding a cure? Simone Fishburn, Chief Editor of BioCentury will lead a C-suite roundtable with Sekar Kathiresan of Verve Therapeutics, Claudia Ulbrich of Cardior Pharmaceuticals, Christopher de Souza of Broadview Ventures, and Michael Mendelsohn of Cardurion Pharmaceuticals.
• Conquering the Next Frontiers in Cancer Therapies: How can we tackle difficult cancers? How do we breach the heterogeneity issue in cancer therapeutic development? Are we delivering on the promise of precision medicine for cancers? These and many more questions will be debated among a leading expert panel, featuring Lewis Williams of Walking Fish Therapeutics, Adam Friedman of Scorpion Therapeutics, Luba Greenwood of Kojin Therapeutics, Rajesh Chopra of Apple Tree Partners, and KT Moortgat of Droia Ventures.
• And more on new modalities, new targets and new enabling platforms…
Complimentary and open to the global healthcare innovation ecosystem, this 3-day program will premiere via Zoom from 8 AM – 11 AM PDT (11 AM – 2 PM EDT) daily on April 26-28.
Click HERE for our speaker bios and program agenda.
Global challenges require global solutions and global collaborations. We hope you will join us for this year’s dynamic discussions.
Best regards,
WuXi Healthcare Forum Committee

Halloran Speaker Series | The Future of RBQM and Customized Key Risk Indicator Libraries: How Small Companies Can Take Big Steps to Reduce Risk and Trial Oversight
2022-04-27 14:00 - 15:00 UTC
Identifying the key risks to be monitored in a clinical study is critical for a successful implementation of a Risk-Based Quality Management process (RBQM), and even more, to the overall success of the clinical trial. Identifying the right Key Risk Indicators (KRIs) is also of utmost importance because they are the risk indicators that enable clinical study teams to proactively make informed decisions along the way. To put it simply, a study team needs the right KRIs to actively monitor the trial’s risks.
We’ve witnessed many small biopharma companies wonder if there are different ways to identify and manage KRIs for their trial, particularly, because many face the challenge of not having enough data to inform KRI selections from the onset. Some companies just don’t have that data and insight, so they often rely on a KRI library from their vendors.
As we zoom out from those observations, we want to share our insights with you on the future of RBQM that will be helpful especially to smaller companies, particularly around the following questions:
If you don’t have enough data to inform decisions on KRIs, where do you start?
How do you implement a risk-based quality management process to inform KRIs?
Should companies have a library of KRIs to utilize from the onset?
What does it look like to overdo it vs. underdo it and why does this viewpoint matter?
How should companies partner with their vendors on KRIs?
How should you develop KRIs if you outsource your studies to CROs?
When should you start developing KRIs and your RBQM processes?
What does the future of customized risk management look like?
We invite you to this conversation on Thursday, April 27th from 2-3 pm ET on “The Future of RBQM and Customized Key Risk Indicator Libraries How Small Companies Can Take Big Steps to Reduce Risk and Provide Trial Oversight” led by Sheila Gwizdak, VP of Quality at Halloran Consulting Group, and members of the Organizational Quality Solutions and Clinical teams during our Halloran-hosted Speaker Series.

Virtual BioXchange April 27
2022-04-27 16:00 - 19:00
Miss being able to network with colleagues in the life science industry? We have you covered with the best virtual networking experience through Grapevine Network’s networking platform. Connect with life science colleagues from all over the world.
BioXchange has gone virtual to allow the best online opportunity to interact with individuals from throughout the life science industry. The event will be hosted on Grapevine Network’s platform which provides an amazing experience that allows attendees the freedom to navigate between different group discussions within an interactive chatroom environment. The platform provides the closest experience to a live networking experience.
Participants are welcome to join the event at any point of time. The event is subject to run later than the posted end time as the room will stay open as long as people are actively engaged within the chat room.
***Event is expected to sell out and NOT ALL RVSPS ARE GUARANTEED ENTRY into the event due to the limited attendee capacity offered on the platform.
